The 5-year disease-free survival rates of patients with or without mutations in the PI3K/AKT pathway genes were not significantly different (35.9% vs. 47.2% for patients with vs. without mutations, respectively; P=0.156), and those of the two groups with either early gastric cancer (T1 tumors, 80% vs. 83.6%, P=0.800) or advanced gastric cancer (T2-T4 tumors, 31.0% vs. 40.1%, P=0.235) were also not significantly different. The gene discussed is AKT1; the disease is gastric cancer.